With the current emphasis on defined vaccines composed of protein subunits, there is a persistent need to improve the stability and performance of vaccines. Most vaccines are formulated in aqueous buffers and suspensions with aluminum salts adjuvants, vaccine immunogens degrade and lose potency (and efficacy). Elevated temperature increases the rate of protein degradation. As a result, liquid vaccines must be stored under refrigerated or frozen conditions. A well-controlled environmental cold chain must be maintained from the point of manufacture to the ultimate vaccinee. Temperature control will ultimately not be satisfactory in situations where vaccines are rarely used or not widely distributed especially where the vaccines are to be stockpiled for use for biodefense. The goal of this proposal is to develop processes and specific thermally stable formulations for two biodefense subunit vaccines adsorbed to aluminum adjuvants. This will be accomplished by using a drying technology and excipients that prevent the aggregation of aluminum adjuvant particles during freeze-drying and subsequent storage, while also preserving the structural and chemical integrity of the antigen. The vaccine subunits for study and development, a Ricin A chain vaccine (RTA V76M/Y80A, RiVax(tm)) and a hyperimmunogenic mutant (DNI, dominant negative inhibitor) of B. anthracis protective antigen (PA), are overall well characterized in physical and immunological properties. The first goal of this proposal is to develop and characterize the terminal step in manufacture of the vaccines, which would comprise lyophilization aluminum hydroxide-adsorbed subunit vaccines in the presence of stabilizing excipients, permitting retention of structure of the immunogens and functionality of the adjuvant. The second goal of this proposal is to develop vaccines that are more effective by employing well-characterized co-adjuvants that can be added to aluminum adjuvants subunits. This is expected to result in dried thermostable subunit vaccines that can be given in an accelerated regimen (fewer numbers of doses) and which result in more rapid onset of protective immunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI082210-05
Application #
8531131
Study Section
Special Emphasis Panel (ZAI1-BLG-M (J2))
Program Officer
Baqar, Shahida
Project Start
2009-09-24
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$1,182,630
Indirect Cost
$205,250
Name
Soligenix, Inc.
Department
Type
DUNS #
153880778
City
Princeton
State
NJ
Country
United States
Zip Code
08540
Wahome, Newton; Sully, Erin; Singer, Christopher et al. (2016) Novel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice. J Pharm Sci 105:1603-13
Blohmke, Christoph J; Darton, Thomas C; Jones, Claire et al. (2016) Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. J Exp Med 213:1061-77
Roy, Chad J; Brey, Robert N; Mantis, Nicholas J et al. (2015) Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection. Proc Natl Acad Sci U S A 112:3782-7
Vance, David J; Rong, Yinghui; Brey 3rd, Robert N et al. (2015) Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice. Vaccine 33:417-21
Pincus, Seth H; Bhaskaran, Manoj; Brey 3rd, Robert N et al. (2015) Clinical and Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin. Toxins (Basel) 7:2121-33
Hassett, Kimberly J; Vance, David J; Jain, Nishant K et al. (2015) Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants. J Pharm Sci 104:627-39
Greene, Christopher J; Chadwick, Chrystal M; Mandell, Lorrie M et al. (2013) LT-IIb(T13I), a non-toxic type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity. PLoS One 8:e69678
Thomas, Justin C; O'Hara, Joanne M; Hu, Lei et al. (2013) Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen. Hum Vaccin Immunother 9:744-52
Hassett, Kimberly J; Cousins, Megan C; Rabia, Lilia A et al. (2013) Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization. Eur J Pharm Biopharm 85:279-86
Iyer, Vidyashankara; Hu, Lei; Schanté, Carole E et al. (2013) Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine. Hum Vaccin Immunother 9:2362-70

Showing the most recent 10 out of 13 publications